Recently, the FUTURE series of studies has brought good news again. The results of the FUTURE-SUPER clinical trial led by the team of Prof. Zhimin Shao and Prof. Zhonghua Wang from the Affiliated Cancer Hospital of Fudan University have been announced, which fully confirmed the effectiveness and safety of the first-line precision treatment based on the "Fudan typing", and is about to change the clinical practice of the treatment of TNBC. The results of the study will be announced in 2023. The results of the study were first announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2023, which attracted the attention of scholars around the world, and on January 9, 2024, the study was published in The Lancet Oncology, the top international oncology journal, with an impact factor as high as 51.1 under a fast-track system.

The clinical study is also another landmark achievement of the development of industry-medicine integration in Fudan University Cancer Hospital. In the study, the cutting-edge clinical trials of the first-class oncology center and the innovative drugs of Hengrui Pharmaceuticals and other large-scale pharmaceutical companies are "seamlessly connected", and the research team "joins forces" to continuously explore the advantageous therapeutic targets and optimize the therapeutic strategies, which will ultimately improve the prognosis of breast cancer patients, realizing the whole chain from basic to clinical. The whole chain from basic to clinical "closed-loop" innovation research mode has been realized. Hengrui Pharmaceuticals' self-developed HER1, HER2, HER4 tyrosine kinase inhibitor (TKI) pyrrolitinib, humanized PD-1 monoclonal antibody karelizumab, and small molecule multi-targeted tyrosine kinase inhibitor famitinib and other drugs have contributed to the development of FUTURE series research, and have demonstrated excellent therapeutic efficacy, which has brought new choices for TNBC patients in China.

Triple-negative breast cancer has a high risk of recurrence, poor prognosis and high heterogeneity, and traditional chemotherapy strategy can hardly meet the clinical needs; precision treatment strategy based on "Fudan typing" is breaking through the bottleneck of therapeutic efficacy, and it is expected to lead the change of breast cancer diagnosis and treatment mode. As one of the leading figures in the field of breast cancer treatment in China, Prof. Shao Zhimin, with the goal of exploring the precise typing of breast cancer, has led his team to deepen the innovation for many years, and has formed a complete closed loop of basic research to clinical translation, from "Fudan typing" to "FUTURE-SUPER". From "Fudan typing" to "FUTURE-SUPER", the team has formed a complete closed loop from basic research to clinical transformation, fully realized program innovation, theoretical innovation and cooperation innovation, and brought benefits to patients while making a loud "Chinese voice" on the international stage. It is believed that in the near future, more "Chinese solutions" will shine brightly and change the treatment pattern of breast cancer.

网址：https://mp.weixin.qq.com/s/uz-j6WWpTxu8jCLNUV_Ggg